Roth Capital Issues Optimistic Estimate for PolyPid Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Stock analysts at Roth Capital raised their FY2025 EPS estimates for PolyPid in a research report issued on Thursday, November 13th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($2.16) for the year, up from their previous estimate of ($2.81). Roth Capital currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. Roth Capital also issued estimates for PolyPid’s Q4 2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

A number of other research firms have also recently commented on PYPD. Weiss Ratings reiterated a “sell (e+)” rating on shares of PolyPid in a report on Wednesday, October 8th. Craig Hallum reaffirmed a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of PolyPid in a research report on Thursday, August 14th. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Sunday. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.40.

PolyPid Price Performance

PolyPid stock opened at $3.59 on Monday. The company’s 50-day moving average is $3.49 and its 200-day moving average is $3.36. The firm has a market capitalization of $57.08 million, a PE ratio of -1.20 and a beta of 1.53. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $3.93.

PolyPid (NASDAQ:PYPD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.17.

Institutional Trading of PolyPid

Institutional investors have recently bought and sold shares of the business. AIGH Capital Management LLC grew its position in shares of PolyPid by 13.6% during the 1st quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock worth $2,548,000 after purchasing an additional 112,514 shares in the last quarter. Lumbard & Kellner LLC bought a new stake in shares of PolyPid in the second quarter valued at approximately $135,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of PolyPid by 56.1% in the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after buying an additional 3,500 shares during the period. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.